Century Communit. Stock
Price
Target price
€49.40
€49.40
1.000%
0.5
1.000%
-
23.12.25 / Tradegate
WKN: A114W9 / Name: Century / Stock / Homebuilding & Construction Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Century Communit. Stock
The Century Communit. stock is trending slightly upwards today, with an increase of €0.50 (1.000%) compared to yesterday's price.
Pros and Cons of Century Communit. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Century Communit. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Century Communit. | 1.000% | - | -10.991% | -29.429% | -29.429% | - | - |
| Tri Pointe Homes | -2.960% | 1.504% | -7.534% | -21.053% | -21.053% | 56.069% | 87.500% |
| M/i Homes Inc. | 0.510% | 1.438% | -2.410% | -14.033% | -14.033% | 154.302% | - |
| Lgi Homes Inc. | -0.540% | 1.667% | -19.737% | -57.193% | -57.193% | -57.163% | - |
News
Why Century Aluminum Stock Soared Higher Today
Friday is turning out to be a great day to own shares of Century Aluminum (NASDAQ: CENX) -- one day after the metals producer reported earning nearly twice Wall Street's forecast for Q3.
Heading
Why Century Aluminum Stock Blasted Almost 13% Higher on Wednesday
Like the metal in which it specializes, Century Aluminum (NASDAQ: CENX) was solid on Wednesday. Investors piled into the stock following the initiation of coverage by one of America's top banks
Century Reports Flat Loss in Fiscal Q2
Century Therapeutics (NASDAQ:IPSC), an early-stage biotechnology company pioneering cell therapies using induced pluripotent stem cell (iPSC) technology, reported its second quarter 2025 financial